Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eliglustat PK Dose Proportionality in Healthy CYP2D6 Metabolizers
NCT06188325Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jan 2018
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of eliglustat in Gaucher disease (GD) (2 arms), sponsored by Sanofi. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 2 more. Started Jan 2018; status: completed.
02
Drugs
eliglustat
03
Conditions
Gaucher disease (GD)
Beyond the preview
Go deeper on NCT06188325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06188325.